<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376311</url>
  </required_header>
  <id_info>
    <org_study_id>Daniel H Manicourt</org_study_id>
    <nct_id>NCT00376311</nct_id>
  </id_info>
  <brief_title>Effects of Oral Salmon Calcitonin in Human Osteoarthritis</brief_title>
  <official_title>Phase IIa Study of the Effects of a New Oral Formulation of Salmon Calcitonin in Human Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and clinical efficacy of oral salmon calcitonin in
      patients suffering from osteoarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) is a difficult condition to manage and, thus far, we have no simple,
      effective interventions for this common cause of pain and disability.

      Because parenteral salmon calcitonin (sCT) has positive effects in canine experimental OA,
      this phase IIa, randomized,placebo-controlled, double-blind trial evaluates the safety,
      tolerance and clinical efficacy of an oral formulation of sCT in patients with OA.

      Patients receive a tablet containing either a placebo, 0.5 mg sCT or 1 mg sCT that they have
      to take every day in the morning 15 minutes before breakfast for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>May 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lequesne's algofunctional index</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers of joint metabolism</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance</measure>
  </secondary_outcome>
  <enrollment>54</enrollment>
  <condition>Osteoarthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral salmon calcitonin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  radiographic OA according to the criteria of the American College of Rheumatology;

          -  morning joint stiffness between 15 and 30 minutes;

          -  pain on weight bearing and motion reported greater than 40 mm on a 0-100 mm visual
             analogue scale;

          -  normal liver and kidney function tests;

          -  serum CRP levels &lt; 10 mg/l

        Exclusion Criteria:

          -  previous or ongoing treatment with anti-resorptive drugs such as bisphosphonates,
             estrogen or raloxifene

          -  crystal deposition diseases

          -  known hereditary or congenital defects

          -  clinically significant hepatic, renal, cardiovascular, psychiatric, endocrine and/or
             hematological diseases

          -  intra-articular injections of either corticosteroids (previous 3 months) or hyaluronan
             (previous 6 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H Manicourt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Rheumatology, University hospital St Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luc University Hospital, Department of Rheumatology, Université Catholique de Louvain</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Lequesne's algo-functional score</keyword>
  <keyword>Biomarkers of joint metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

